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Abstract. A  complete set of chimeras was made be~ 
tween the lysosomal membrane glycoprotein LEP100 
and the plasma membrane-directed vesicular stomatitis 
virus G protein, combining a glycosylated lumenal or 
ectodomain, a single transmembrane domain, and a 
cytosolic carboxyl-terrninal domain. These chimeras, 
the parent molecules, and a truncated form of LEPI00 
lacking the transmembrane and cytosolic domains 
were expressed in mouse L cells. Only LEP100 and 
chimeras that included the cytosolic 11 amino acid 
carboxyl terminus of LEP100 were targeted to lyso- 
somes. The other chimeras accumulated in the plasma 
membrane, and truncated LEP100 was secreted. 
Chimeras that included the extracellular domain of 
vesicular stomatitis G protein and the carboxyl termi- 
nus of LEP100 were targeted to lysosomes and very 
rapidly degraded. Therefore, in chimera-expressing 
cells, virtually all the chimeric molecules were newly 
synthesized and still  in the biosynthesis and lysosomal 
targeting pathways. The behavior of one of these 
chimeras was studied in detail. After its processing in 
the Golgi apparatus, the chimera entered the plasma 
membrane/endosome compartment and rapidly cycled 
between the plasma membrane and endosomes before 
going to lysosomes. In pulse-expression experiments, a 
large population of chimeric molecules was observed 
to appear transiently in the plasma membrane by im- 
munofluorescence microscopy. Soon after protein syn- 
thesis was inhibited, this surface population disap- 
peared. When lysosomal proteolysis was inhibited, 
chimeric molecules accumulated in lysosomes. These 
data suggest that the plasma membrane/early endo- 
some compartment is on the pathway to the lysosomal 
membrane. This explains why mutations that block 
endocytosis result in the accumulation of lysosomal 
membrane proteins in the plasma membrane. 
T 
HE limiting membrane of the lysosome is greatly en- 
riched in a class of heavily glycosylated,  extensively 
sialylated integral  membrane proteins (reviewed  in 
Kornfeld and Mellman,  1989). Although the function of 
these glycoproteins is not known, they may protect the lyso- 
somal membrane from hydrolysis (Kornfeld and Mellman, 
1989; Granger et al.,  1990). These glycoproteins  are also 
found in lower abundance in endocytic vesicles and in the 
plasma membrane (Lippincott-Schwartz  and  Fambrough, 
1987; Griffiths et al.,  1988; Mane et al.,  1989). The avian 
lysosomal membrane glycoprotein LEP100 and its encoding 
DNA  have  been  characterized (Lippincott-Schwartz  and 
Fambrough, 1986, 1987; Fambrough et al.,  1988; Zot and 
Fambrough,  1990). LEP100 has a cleaved amino-terminal 
signal peptide,  a lumenal domain of 361 amino acids with 
17 N-linked oligosaccharides,  a single transmembrane do- 
main of 24 amino acids, and a cytoplasmic carboxyl termi- 
nus of 11  amino acids.  Homologues  of LEP100 occur in 
mammals, including human hLAMP-1 (Viitala et al., 1988; 
Fukuda et al.,  1988),  rat lgpl20 (Howe et al.  1988), and 
mouse mLAMP-1 (Chen et al., 1988). Amino acid sequence 
similarity among these four lysosomal membrane glycopro- 
teins increases from the amino terminus to the carboxyl ter- 
minus, with the cytoplasmic domain showing complete se- 
quence identity. 
The intracellular trafficking leading to the lysosomal deliv- 
ery of many soluble lysosomal enzymes involves the man- 
nose  6-phosphate  (M6P) t  signal/receptor system.  Newly 
synthesized lysosomal enzymes are modified by the addition 
of phosphate to the 6-hydroxy position on mannose residues 
(von Figura and Hasilik,  1986). This M6P signal is recog- 
n.zed by the M6P receptor in the trans-Golgi  network (TGN) 
(Griffiths and Simons, 1986), and M6P-tagged enzymes are 
transported by vesicular traffic to late endosomes (Leman- 
sky et al.,  1987; Marquardt et al.,  1987; Griffiths et al., 
1988). Here the enzymes dissociate from their receptor and 
are transported on to lysosomes while the receptor is recy- 
cled to the TGN (Brown et al., 1986; Duncan and Kornfeld, 
1988; Goda and Pfeffer, 1988). The lysosomal membrane 
glycoproteins,  however, do not contain the M6P modifica- 
tion and must be targeted to lysosomes by a different mecha- 
nism (D'Souza and August,  1986; Lippincott-Schwartz  and 
I. Abbreviations used in this paper: CHX, cycloheximide; LAE lysosomal 
acid phosphatase; M6P, mannose 6-phosphate; TGN, trans-Golgi network; 
VSV-G, vesicular  stomatitis  virus coat glycoprotein. 
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1990). 
Previous reports have documented the lysosomal targeting 
of chimeric  proteins  consisting  of the  ectodomain  of a 
plasma membrane protein linked to the transmembrane and 
cytoplasmic domains of LEP100 or the cytoplasmic domain 
ofhLAMP-1 (Mathews, P. M., and D. M. Fambrough, 1988. 
J. Gen. Phys. 92:18a; Williams and Fukuda, 1990).  We re- 
port here on a complete battery of chimeras between LEP100 
and the plasma membrane protein vesicular stomatitis virus 
coat glycoprotein (VSV-G) in which each of the three do- 
mains of LEP100 was replaced by the corresponding domain 
of  VSV-G and vice versa. The behavior of these chimeras and 
a truncated form of LEP100 that was secreted suggests that 
only the 11-amino acid cytoplasmic domain of LEP100 is in- 
volved in lysosomal targeting. 
The mechanism whereby the cytoplasmic tail of LEP100 
directs the lysosomal targeting of newly synthesized mole- 
cules remains unknown. The single tyrosine in the cytoplas- 
mic tail has been shown to be necessary for the lysosomal 
targeting of hLAMP-1  and lgpl20.  Mutating this tyrosine 
resulted in proteins that accumulate in the plasma mem- 
brane,  as did eliminating most of the cytoplasmic tail of 
hLAMP-1  (Williams and Fukuda,  1990;  Hunziker et al., 
1991).  This mistargeting has been interpreted as resulting 
from a defect in sorting in the TGN: newly synthesized mole- 
cules fail to target to lysosomes at the TGN and are therefore 
transported to the plasma membrane along the constitutive 
secretory pathway. This interpretation was based predomi- 
nantly on the work of Green et al. (1987), in which metaboli- 
cally  labeled  lgpl20  was  found  to  appear  rapidly  in  a 
lysosomal subcellular fraction, and very little lgpl20 was 
found in the plasma membrane and early endosomes. Re- 
cently Harter and Mellman (1992) revised this interpreta- 
tion, proposing a branched pathway of targeting of lgpl20 
partly via the TGN to late endosomes and lysosomes and 
partly via the plasma membrane. 
Contrary to these interpretations, recent experiments indi- 
cate that most or all molecules of a  very closely related 
lysosomal membrane glycoprotein (LAMP-2) pass through 
the basolateral plasma membrane of polarized MDCK cells 
before lysosomal delivery (Nabi et al., 1991). LAMP-2 mol- 
ecules, which share some sequence identity with LEP100, 
have been  cloned from a  number of mammalian species 
(Fukuda et al.,  1988;  Cha et al.,  1990;  Granger et al., 
1990).  Another lysosomal protein, human lysosomal acid 
phosphatase (LAP), travels to the plasma membrane as an 
integral membrane protein prior to endocytosis, lysosomal 
delivery, and cleavage to  a  soluble form (Waheed et al., 
1988;  Braun et al.,  1989).  In our study we made use of a 
LEP100 deletion mutant and chimeras between LEP100 and 
VSV-G protein to study the pathway by which the lysosomal 
targeting signal in LEP100 directs molecules to the lyso- 
somes. These three cases (LAMP-2, LAP, and LEPI00) sug- 
gest that the delivery of integral membrane proteins to the 
lysosome via the cell surface is a major pathway in animal 
cells. 
Materials and Methods 
Mutagenesis and Construction of Chimeric cD  NAs 
The eDNA encoding VSV-G was the generous gift of Dr. J. K. Rose (Yale 
University School of Medicine, New Haven, CT) (Rose and Shafferman, 
1981; Rose and Bergmann, 1982). Mutations creating unique restriction en- 
donuclease sites were introduced by the method of Kunkel et al. (1987). 
Briefly, dUTP-containing single stranded eDNA was prepared, mutagenic 
synthetic oligonucleotides were used to prime second strand synthesis, and 
mutated DNA was recovered after transforming dUTP-intolerant bacteria. 
A PvuII restriction site was introduced into the VSV-G eDNA just 5' to the 
region encoding the transmembrane domain; this site is in-frame with a 
unique PvuII site located just 5' to the region encoding the transmembrane 
domain in the LEP100 eDNA. HpaI sites were introduced into both cDNAs 
near the 3' end of  the region encoding the transmembrane domain. Chimeric 
cDNAs were constructed using these restriction sites (see Fig.  1). 
The chimera in which the cytoplasmic domain of LEP100 replaced that 
of VSV-G  was constructed using the polymerase chain reaction (PCR) 
(Saiki et al., 1988).  A hybrid primer with the sequence 5'-GGA CTA TIC 
TTG GTT CTC AGA AAG AGG AGC CAC-3' was used to generate a 448- 
bp fragment consisting of a  18-bp region of identity to the Y-most trans- 
membrane encoding region of VSV-G, the entire cytoplasmic domain and 
3' untranslated regions of the LEP100 eDNA, and an additional 68 lap ex- 
tending beyond the polylinker in pSVDF-4 (see below). This fragment was 
isolated and used as primers with VSV-G cDNA in the Bluescript vector 
(Stratagene, La Joila, CA) for six PCR cycles. Then a large fragment encod- 
ing most of the lumenal and all of the transmembrane regions of  VSV-G and 
the cytoplasmic domain of LEP100 was generated by adding appropriate 
primers and carrying out 30 additional PeR cycles. This fragment was cut 
with NcoI and EcoRl and cloned into Bluescript containing the 5'-609 bp 
of VSV-G (up to the unique Ncol site). 
To generate the DNA encoding a secretory form of LEP100, a PCR frag- 
ment representing just the lumenal encoding domain of LEP100 was gener- 
ated, using as 3' end primer the oligonucleotide 5'-AGG GAA TIE TTA 
CTA CAT GTT GTT TTC ATe CAG-3' that introduced two tandem stop 
codons followed by an EcoRl site after the last codon preceding the trans- 
membrane encoding region. This fragment was digested with BglII and 
EcoR1  and  cloned into  the Bluescript vector containing the 5'-790-bp 
EcoR1-BglII fragment of the LEPI00 cDNA. 
The nucleotide sequences of all the splice regions of the chimeric DNAs 
and all the PCR-generated coding regions were confirmed by DNA sequenc- 
ing (Sanger et al.,  1977).  The structures of the normal, mutant, and chi- 
meric proteins are summarized in Fig. 1 along with the nomenclature used 
for them in this report. 
Expression  of DNAs in Ltk- Cells 
Mouse Ltk- cells (Kit et al.,  1963) were maintained in DME,  10%  FBS, 
and 50 #g/ml gentamicin (Gibco Laboratories, Grand Island, NY) at 37~ 
in a 5 % CO2 atmosphere. 
The cDNAs encoding LEPI00, VSV-G,  and the chimeras were cloned 
into the mammalian expression vector pSVDF-4 (Takeyasu  et al.,  1987), 
permitting butyrate-inducible expression driven by the SV-40  early pro- 
moter (Gorman et al.,  1983).  For stable lines, mouse Ltk- cells were co- 
transfected  using  either  a  calcium  phosphate  precipitate  (Small  and 
Scangos, 1984) or lipofectin (Gibco-BRL, Rockville, MD) used according 
to manufacturers protocol, with ,x, 20/~g of expression plasmid DNA and 
2/~g of pHSVtk5' A 0.2 DNA (McKnight, 1980) per 100-mm tissue culture 
dish of sub-confluent Ltk- cells. After 24 h the medium was replaced by 
HAT  medium (Boehringer Mannheim Biochemicals, Indianapolis,  IN). 
HAT-resistant clones (Littlefield, 1964)  were isolated, expanded, and as- 
sayed for expression of LEP100 or VSV-G epitopes by immunofluorescenee 
microscopy. 
The eDNA encoding truncated LEP100 was cloned into an EcoR1  site 
introduced just 3' of the human cytomegalovirus immediate early promoter 
in the expression vector pCB6 (Brewer and Roth,  1991). L cell lines ex- 
pressing truncated LEP100 were established by lipofectin-mediated trans- 
fection and selection in 400 t~g/ml G418  (Sigma Chemical Co., St. Louis, 
MO) in DME 10% FBS. Approximately 150 colonies from a single 100- 
mm tissue culture dish were pooled for use in immunofluorescence and 
metabolic labeling experiments. Expression required butyrate induction (10 
mM for 24 to 48 h). 
Transient expression was employed in some immunofluorescence  experi- 
ments.  L  cells were plated on glass coverslips in 35-mm tissue culture 
dishes, 4/zg DNA was added as lipofectin/DNA complex in 1 ml DME, 
1 ml DME with  10%  FBS was added 4  h  later, and at 24 h the growth 
medium was replaced with DME 10% FBS containing 10 mM butyrate. Af- 
ter an additional 36 to 48 h these cultures were used for inununofluores- 
cenee microscopy. The recombinant vaccinia virus/T7 RNA polymerase ex- 
pression system (Fuerst et al., 1986; Moss, 1991) was used for short-term 
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Bluescript vector downstream from the 1"7  promoter.  Newly confluent 
Ltk- cells growing on 25-mm-diam glass coverslips were infected with the 
recombinant vaccinla virus at a multiplicity of 10 pfu/cell in 0.6 ml DME. 
30 min later, transfection was begun by adding 4 to 5 #g DNA, 10 #1 lipofec- 
tin in 1 mi DME. After 4 h,  1 ml DME  10%  FBS was added. In "pulse 
expression" experiments (see Results),  75  /~g/ml  cycloheximide (Sigma 
Chemical Co.) was added at this time. When leupeptin was used to prevent 
lysosomal degradation of the  ectodomaln of VSV-G,  20  ttM  leupeptin 
(Sigma Chemical Co.) was added 3 to 4 h before infection and maintained 
throughout the experiment. 
Immunofluorescence Microscopy 
Anti-LEP100 monoclonal IgG (LEP100-mAb) (Lippincott-Schwartz and 
Fambrough, 1986) recognizes a lumenal epitope on LEP100 and does not 
cross-react with murine Ltk- cells, mAb I1 (VSV-G-mAb), the hybridoma 
a gift of Dr. D. S. Lyles (Bowman Gray School of Medicine, Wake Forest 
University,  Winston-Salem, NC), binds to an extracellular epitope of VSV-G 
(LeFrancois and Lyles, 1982).  Antibodies were purified from ascites fluid 
as previously described by Lippincott-Schwartz and Fambrough (1986). 
FITC or TR1TC (Molecular Probes, Eugene, OR) was conjugated to purified 
antibody as described by Anderson and Fambrough (1983). FITC and TRITC- 
conjugated goat anti-monse-IgG sera were purchased from Cappel Labora- 
tories (Malvern, PA).  For location of endogenous m-LAMPI in mouse L 
cells, rat monoclonal anti-m-LAMP1 (Chen et al.,  1985) and FITC-con- 
jugated goat anti-rat-IgG serum (Cappel Laboratories) were used. 
Cells grown on 25-mm coverslips were fixed in 1% fresh formaldehyde, 
100 mM sucrose, 20 mM Na phosphate (pH 7.2) at room temperature for 
10 min, rinsed, labeled for 30-60 min with 5 ttg/mi mAb in Hepes-buffered 
(20 mM pH 7.2) MEM containing 10% horse serum, and washed repeatedly 
with Hepes/MEM containing 10% horse serum. Cells were permeabilized 
by the addition of 0.125%  saponln (wt/vol) (Sigma Chemical Co.) to the 
antibody containing and the wash solutions. For indirect immunnfluores- 
cence labeling, coverslips were washed after primary antibody binding, and 
secondary antibody was then bound followed by 30 min of washes. Cells 
were mounted in 90% glycerol, 10%  PBS,  1 mg/ml p-phenylene diamine 
and examined with a (Carl Zeiss, Oberkochen, Germany) epifluorescence 
microscope. 
Metabolic Labeling and Immunoprecipitation 
Approximately 5  x  105 cells were plated in 35-ram tissue culture dishes 
and after 16 h were induced with 10 mM butyrate for 36 to 48 h. Cultures 
were incubated in methionine-free  MEM containing 10 mM butyrate for 30 
min before a 15-rain incubation with 100-200 #Ci/mi [35S]methionine  and 
[35S]cysteine  (TRANa5S-LABEL)  (ICN Biomedicals, Inc., Costa Mesa, 
CA). After four rinses with DME 10%  FBS at 4~  cells were grown in 
DME, 10% FBS for the chase times specified in the text. For some experi- 
ments, cells were treated with 20 #M leupeptin beginning 4-5 h before me- 
thionine starvation and continuing through the labeling and chase periods. 
35S-labeled ceils were rinsed once with PBS, extracted with 1 ml buffer 
A (150 mM NaC1,  50 mM Tris,  10 mM EDTA,  1% Triton X-100, pH 7.5) 
containing protease inhibitors (0.3 mg/ml benzamidine, 0.6 mg/ml N-ethyl- 
maleimide,  1.0 mg/mi bacitracin), and the extracts were frozen. Extracts 
were thawed and centrifuged at  12,000 g  10 rnin. Each superuatant was 
mixed with 50/~g mAb covalently coupled to Sepharose 4B beads (Fam- 
brough and Bayne,  1983)  and incubated at 4~  overnight. Imrnunobeads 
were washed eight times with buffer A, twice with PBS, and eluted with 
SDS sample buffer (10%  [vol/vol]  glycerol, 30 mg/mi SDS, 5%  [vol/vol] 
2-mercaptoethanol, 62 mM Tris, pH 6.8).  Immune precipitates were ana- 
lyzed by  SDS-PAGE and  fluorography.  Radioactivity  in  the bands  was 
quantified with a  Molecular Dynamics PhosphorImager and the Image- 
Quant software package. 
12~I-mAb Binding 
Sodium  [125]iodide  was  purchased  from  Amersham  Corp.  (Arlington 
Heights,  IL),  Iodogen from Pierce Chemical Company (Rockford, IL). 
Purified monoclonal IgGs were iodinated by the Iodogen method (Salicinski 
et al., 1981).  Specific activities of iodinated antibodies were determined 
from knowledge of the antibody concentration (input antibody amount de- 
termined spectrophotometrically) and the radioactivity measured in ali- 
quots of the antibody solution after iodination. These values were typically 
on the order of 1 cpm/106 antibody molecules. Cells grown in 35-mm tis- 
sue culture dishes were fixed at room temperature for 10 rain (as for im- 
munofluorescence microscopy) and  incubated for  1-2  h  with  125I-mAb 
(5 ttg/ml) in MEM,  10%  horse serum, 20 mM Hepes (pH 7.2).  After un- 
bound antibody was removed by three 10 min washes in 1-2 liters of medium 
at 4~  bound t25I-mAb was eluted with 2 ml of 1 N NaOH and counted 
in a gamma counter. To permeabilize cells, saponin (0.125%  wt/vol) was 
added to the binding medium. Non-specific binding was determined using 
a 50- or 100-fold excess unlabeled mAb in the binding solution. Data points 
represent the average of two or three measurements of non-specific binding 
subtracted from the average of three to five measurements of total binding. 
Results 
Only LEPIOO/VSV-G Chimeras 
Containing the Cytoplasmic Domain of  LEPIO0 
Are Targeted to Lysosomes 
VSV-G was chosen for the construction of chimeric mole- 
cules  because  of the  overall  similarity  in  topography to 
LEP100, and because, unlike LEP100, VSV-G accumulates 
in the plasma membrane of transfected cells (Rose and Berg- 
mann,  1982). Chimeric cDNAs were constructed in which 
regions of the DNA encoding the three domains of LEP100 
(lumenal, transmembrane, and cytoplasmic) were replaced 
singly and in combinations by DNA  encoding the corre- 
sponding domains of VSV-G (Fig. 1). The resulting chimeras 
were expressed in mouse L cells, and their cellular locations 
were determined by immunofluorescence microscopy with 
monoclonal antibodies  specific for either the lumenal do- 
main of LEP100 or the extracellular domain of VSV-G. For 
all chimeras containing the ectodomain of VSV-G, the pro- 
tease inhibitor leupeptin was added to cells 16 h before fixa- 
tion to prevent proteolytic destruction of this domain in lyso- 
somes  (see  below).  When  expressed  in  L  cells  (Fig.  2) 
VSV-G showed the expected cell-surface localization, while 
LEP100 showed a lysosomal distribution. (In numerous ex- 
periments co-localization of LEP100 and endogenous mouse 
LAMP-1 was found; occasionally one or two internal struc- 
tures  showed  selective  immunolabeling  with  LEP100  or 
LAMP-1.) 
Three of the chimeras (L/V/V, L/L/V, and V/L/V) accu- 
mulated in the plasma membrane (Fig. 2). These chimeras 
have in common the cytoplasmic domain of VSV-G. The ap- 
parent cell surface distribution of VSV-G, L/V/V, and L/L/V 
was  quantified by  ~25I-VSV-G mAb  binding  to  intact and 
permeabilized cells.  After 48 h  of butyrate induction and 
16 h of leupeptin treatment, >/75  % of molecules were in the 
plasma membrane (Table I). 
The three chimeras incorporating the cytoplasmic domain 
of LEP100 (V/L/L, V/V/L, and L/V/L) accumulated in lyso- 
somes  (Fig.  2),  co-localizing  with  mLAMP1.  Although 
LEP100 and V/L/L were predominantly intracellular,  t25I- 
antibody binding experiments detected some molecules at 
the cell surface (Table I). The presence of these molecules 
in  the  plasma  membrane  is  similar  to  the  situation  for 
LEP100 in chicken embryo fibroblasts,  where ~2-3%  of 
molecules were found on the surface (Lippincott-Schwartz 
and Fambrough,  1986,  1987). 
The Lumenal Domain of  LEPIO0 Is Secreted When 
Expressed as a Truncated Protein 
The lumenal domain of LEP100 appears to lack lysosomal 
targeting information, since L/V/V and L/L/V chimeras do 
not accumulate in lysosomes. However, it is possible that tar- 
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Figure 1.  Nomenclature  and 
amino acid sequences of LEP- 
100/VSV-G chimeric proteins. 
The amino acid sequences for 
LEP100, VSV-G, and the chi- 
meras are shown beginning a 
few amino acid amino termi- 
nal to the transmembrane do- 
main (shaded). Constructions 
of chimeras employed PvulI 
sites in the DNA encoding the 
lumenal  domain  of LEPI00 
and the extracellular domain 
of VSV-G and Hpa I sites in 
the DNA encoding the trans- 
membrane  domains  (arrows 
indicate corresponding amino 
acid locations). Chimeras are 
named according  to the scheme 
lumenal-extracellular domain/ 
transmembrane domain/cyto- 
plasmic domain with "L" for 
LEP100 and "V" for VSV-G; 
e.g., L/V/L consists of the lumenal domain of LEP100/transmembrane domain of VSV-G/cytoplasmic domain of LEP100. Truncated 
LEP100 consists of the entire lumenal domain without the transmembrane of cytoplasmic domains. The asparagine residue (underlined) 
in the transmembrane domain of L/L/V, V/L/V and L/V/L is an amino acid change resulting from the generation of the HpaI site. 
geting information in the lumenal domain of LEP100 might 
be overridden by information in the cytoplasmic domain of 
VSV-G. If the lumenal domain of LEP100 contains intrinsic 
lysosomal targeting information and reaches the lysosome by 
a route analogous to that taken by M6P-tagged lysosomal en- 
zymes, then the lumenal domain expressed alone should ac- 
cumulate in lysosomes. Otherwise, this domain, expressed 
as a truncated protein, should be secreted. To test these pos- 
sibilities, we constructed a truncated LEP100 consisting of 
the entire lumenal domain without the transmembrane and 
cytoplasmic domains (Fig. 1). When truncated LEP100 was 
expressed in mouse L  cells,  immunofluorescence labeling 
revealed a reticular pattern and nuclear ring, indicative of 
predominantly  ER  localization.  No  lysosomal  pattern  of 
labeling was detected even when cells were cultured in the 
presence of leupeptin for 16 h before immunofluorescence 
microscopy; and when cycloheximide was also included in 
the medium for the final few hours, immunoreactivity disap- 
peared, consistent with secretion of truncated LEP100. 
The fate of the truncated LEP100 protein was verified by 
pulse-chase metabolic labeling experiments. After a 30-min 
[35S] methionine, [35S]cysteine pulse but no chase, truncated 
LEP100 was recovered from the cell lysate. The truncated 
LEP100 isolated from the cells was the high mannose inter- 
mediate form, migrating  in SDS-PAGE with an Mr of 85 
kD, 6 kD less than that of the high mannose form of full- 
length LEP100 expressed in L cells. During the chase period 
the amount of  truncated LEP100 associated with the cells de- 
creased rapidly (Fig. 3, A and B). The complex carbohydrate 
form of truncated LEP100 was not apparent in immunopre- 
cipitates from cell lysates even with overexposure of x-ray 
film. However, this form with Mr of 100-110 kD appeared 
in the medium during the  1-2-h chase and remained rela- 
tively stable to 10 h (Fig. 3, A and B). Thus, there appears 
to be no pathway for transport of the lumenal domain of 
LEP100 from the Golgi apparatus to lysosomes. 
The VSV-G Ectodomain of V/L/L Is Rapidly 
Degraded in Lysosomes 
The chimera V/L/L did not accumulate sufficiently in lyso- 
somes for detection by immunofluorescence microscopy ex- 
cept when the protease inhibitor leupeptin was present in the 
medium (see Fig.  2).  Presumably, the VSV-G ectodomain 
was  degraded rapidly upon delivery to the lysosome.  To 
study this,  L  cells from a cell line expressing V/L/L were 
treated for increasing times with leupeptin and total V/L/L 
molecules quantified by ~25I-VSV-G-mAb binding (Fig. 4). 
The number of V/L/L molecules tripled by 12 h, beginning 
a few hours after addition of leupeptin, and doubled again 
by 16 h (see Table II). The lag in accumulation was presum- 
ably due to slow onset of leupeptin inhibition of proteolysis. 
(For this reason, treatment with leupeptin was begun 4 h be- 
fore metabolic labeling or transient expression with the re- 
combinant vaccinia virus/T7 system) (see below). 
If V/L/L molecules are targeted to lysosomes and rapidly 
degraded there, the population of V/L/L in cells not treated 
with leupeptin should be comprised of V/L/L molecules in 
the biosynthetic pathway and in the lysosomal targeting path- 
way. Treatment of expressing ceils with the protein synthesis 
inhibitor cycloheximide (CHX) should result in the disap- 
pearance of V/L/L molecules as they transit these pathways 
and arrive in lysosomes. The kinetics of disappearance of 
V/L/L in CHX-treated cells is shown in Fig.  5.  Approxi- 
mately 80% of the molecules were lost within 90 min. The 
kinetics of loss of V/L/L molecules would be expected to be 
complex,  reflecting  the  transport  of  newly  synthesized 
V/L/L molecules through the biosynthetic pathway and their 
delivery to the lysosome. Transport events preceding deliv- 
ery to the lysosome are likely to be rate limiting and the ac- 
tual degradation of the VSV-G ectodomain in the lysosome 
may be a very rapid event. This interpretation is supported 
by  pulse-chase  metabolic  labeling  experiments described 
below. 
The Journal of Cell Biology, Volume 118,  1992  1030 Figure 2, Immtmofluorescence microscopy of cells expressing chimeric proteins. L cells expressing VSV-G, L/V/V, L/L/V, V/L/V (left 
panel top to bottom), LEP100, V/L/L, V/V/L, and L/V/L (right panel top to bottom) were labeled  with either FITC conjugated VSV-G-mAb 
or LEP100-mAb. All cells were permeabilized  by saponin with the exception of those expressing VSV-G. In order to see lysosomal accumu- 
lation of chimeras containing the ectodomain of VSV-G (V/L/V, V/L/L, and V/V/L), it was necessary to add leupeptin to the cells during 
the latter part of the expression period (generally 16-20 h of leupeptin treatment was chosen). VSV-G, L/V/V, L/L/V, LEP100, and V/L/L 
were expressed in stably transfected L cell lines. V/L/V and L/V/L were expressed in transient expression assays employing lipofectin. 
The chimera V/V/L was expressed using the vaccinia virus/T7 expression system. For this photomicrograph, V/V/L expression was allowed 
to proceed for 4 h, then cycloheximide was added for an additional 4 h, followed by fixation and fluorescent antibody labeling. Protein 
synthesis was blocked with cycloheximide to allow newly synthesized V/V/L molecules to move out of the biosynthetic pathway and into 
lysosomes, simplifying the immunofluoresence pattern.  Bar,  10 #m. 
Mathews et al. Lysosomal Targeting of LEPIO0  1031 Table L Cell Surface Expression ofLEPIO0, VSV-G, 
and Chimeras in Stably Expressing L Cell Lines 
Cell line  Percentage of total 
expressing  binding at cell surface 
VSV G  73.4  +  7.9%* 
L/V/V  86.8  +  2.6%* 
L/L/V  91.7  +  1.7%* 
LEPI00  3.7  +  2.4%  (n  =  2)* 
V/L/L  0.8  +  0.1%  (n  =  3)~ 
Sets of five dishes of cells (3 measurements of total binding, two of non- 
specific  binding)  were incubated  with ~251-1abeled  mAb either with or without 
permeabilization  with saponin, and the percentage  of specific  binding sites on 
the plasma  membrane was determined.  All cell lines were treated with 20 #M 
leupeptin for the final 16 h of a 48 h butyrate induction. 
* (Average surface  binding)/(average  total binding) +  (range  of surface  bind- 
ing)/(average  of total binding), all expressed  as a percentage. 
Mean + standard  error. 
n =  number of independent  experiments. 
In  the  CHX  treatment  experiments  a  small  fraction  of 
V/L/L  molecules  was  relatively  long  lived.  Pulse-chase 
metabolic labeling experiments did not reveal a  subset of 
V/L/L molecules which were long-lived without leupeptin 
treatment (see Fig. 6). Among possible explanations for this 
discrepancy is that CHX  treatment might have resulted in 
depletion of lysosomal hydrolases necessary  for the  rapid 
degradation of the VSV-G ectodomain,  thus extending the 
stability of V/L/L in the lysosome. 
Fig. 6  shows SDS-PAGE analysis of V/L/L from L  cells 
pulse-labeled for 15 min with [35S]methionine and [35S]cys- 
teine followed by various chase times. Without the addition 
of leupeptin, 35S-labeled V/L/L was no longer detected af- 
ter a 2-h chase. This is consistent with the disappearance of 
the majority of VSV-G-mAb binding sites within 90 min af- 
ter the addition of CHX (Fig. 5). Fully glycosylated V/L/L 
first appeared after 20 min of chase, indicating passage into 
Figure 3.  Secretion of a trun- 
cated LEP100. Truncated LEP- 
100 was expressed in a pooled 
population of cell  lines.  (A) 
Expressing cells, grown in 60- 
mm-diam tissue culture dishes 
and butyrate induced for 40 h, 
were metabolically labeled for 
30  min  with  TRANa5S-LA- 
BEL. The chase medium and 
the detergent lysate of  the cells 
at each chase time were incu- 
bated  overnight at 4~  with 
LEP100-mAb  immunobeads. 
Immunobeads  were  washed 
extensively and  bound  mate- 
rial  eluted  directly  in  SDS 
sample buffer and analyzed by 
SDS-PAGE and fluorography. 
(B)  Radioactivity in  electro- 
phoretic bands was quantified 
by  Phosphorlmager  analysis 
and expressed as percentages 
of 35S originally incorporated 
into LEP100 during the pulse. 
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Figure 4.  Accumulation of V/L/L following leupeptin treatment. 
An L cell line expressing the chimera V/L/L was grown in 35-mm- 
diam tissue culture dishes,  induced for 48  h  with butyrate, and 
treated  with 20/~M  leupeptin for the  final portion of this time 
period, as indicated. Each point represents the average of six mea- 
surements of 125I-labeled VSV-G-mAb binding minus the average 
of two measurements of non-specific binding. Specific binding for 
each period of time in medium containing leupeptin was normal- 
ized to the binding in cultures not treated with leupeptin, yielding 
relative numbers of V/L/L molecules in the cultured cells. 
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Figure 5. Stability of V/L/L following cycloheximide block of pro- 
tein synthesis. An L  cell line expressing the chimera V/L/L was 
grown in 35-mm-diam tissue culture dishes, induced with 10 mM 
butyrate for 36 h, and then treated with 75 #g/rnl cycloheximide for 
the indicated times. After fixation, specific binding of I:5I-VSV-G- 
mAb to saponin-permeabilized cells was measured. The data are 
combined from four experiments and each data point represents the 
average of triplicate measurements of total binding minus the aver- 
age of two measurements of non-specific binding. 
Table II. Distribution of V/L/L in Cells with and without 
Leupeptin  Treatment 
12~I-VSV-G-mAb  bound to  ~2~I-VSV-G-mAb  bound to 





(cpm)  (cpm) 
956,000  +  60,000  6,500  +  90 
155,000 +  4,100  5,000 •  550 
Cultures of V/L/L-expressing cells were induced for 48 h with butyrate and 
some cells were treated for the last 16 h with 20/~M leupeptin. The numbers 
of specific total ~I-VSV-G-mAb binding sites and cell surface binding sites 
were determined in saponin permleabilized and non-permeabilized  cells as 
described in Materials and Methods. l.,r  treatment results in some cell 
loss from tissue culture dishes (<20%) as ascertained  by counting cell numbers 
on multiple  duplicate  dishes with and without leupeptin  treatment. The data for 
leupeptin treatment are adjusted to reflect this. 
Figure 6. Biosynthesis and degradation of V/L/L in L cells with and 
without leupeptin treatment. An L cell line expressing V/L/L was 
grown in 35 mm-diameter tissue culture dishes and induced with 
10 mM butyrate for 2 d before a  15 rain metabolic labeling. Chase 
times are indicated. V/L/L was immunoaffinity  purified from deter- 
gent lysates of cells with VSV-G-mAB immunobeads and subjected 
to SDS-PAGE and fluorography. (A) The material immunoprecipi- 
tated from cells without leupeptin treatment. (B) 20 #M leupeptin 
was added to cell cultures 4 h before the metabolic labeling  and then 
maintained throughout  metabolic labeling and  chase.  The high 
marmose intermediate form of V/L/L appears immediately follow- 
ing metabolic labeling while the complex carbohydrate form ap- 
pears during the chase. Additionally, a clipped form with an appar- 
ent molecular weight of '~60 kD is seen following longer chase 
periods in leupeptin treated ceils. The 44-kD band on both gels is 
a contaminant mouse protein always seen when VSV-G-mAb im- 
munobeads were used for V/L/L isolation. 
Mathews et al. Lysosomal Targeting of LEPIO0  1033 the Golgi apparatus by this time. Degradation products, that 
appear in SDS-PAGE as a smeared band migrating ahead of 
the mature form of V/L/L, were apparent after 40 to 50 min 
of chase. In cells treated with leupeptin, asS-labeled V/L/L 
remained throughout a 2.5-h chase period (Fig. 6 B) and was 
still recovered after a  10-h chase. 
A  decrease in apparent molecular weight of 35S-labeled 
V/L/L occurred during the chase  with leupeptin present 
(Fig. 6 B). This indicates that V/L/L was partially degraded 
to a "clipped" form (Mr, 60 kD) that retained the epitope 
recognized by VSV-G-mAb. The clipped protein was •7  kD 
smaUer than fully glycosylated  V/L/L and probably resulted 
from the removal of  the amino terminal region of  the protein, 
since a polyclonal anti-serum raised against a peptide corre- 
sponding to the cytoplasmic tail of LEP100 (Nabi et al., 
1991) bound to the clipped form of V/L/L in immunoblots. 
Removal of the two N-linked oligosaccharides would also re- 
sult in about a 7 kD decrease in molecular weight, a possibil- 
ity which was not ruled out. Clipped V/L/L first appeared 
after 60 to 70 rain of chase and became the only form of the 
molecule present by the end of a  10-h chase period. If the 
clipping occurs in the lysosomes, the delivery of V/L/L to 
lysosomes must begin less than 75 to 85 min after synthesis. 
Taken together, these experiments support the hypothesis 
that V/L/L molecules are targeted to lysosomes through a 
biosynthesis/transport process of 60-80-min duration and 
that,  unless  leupeptin  is  present,  V/L/L  molecules  are 
degraded within minutes of reaching the lysosomes. 
Some Newly Synthesized V/L/L Molecules  Are Found 
at the Cell Surface 
Since V/L/L molecules appear to be degraded quickly upon 
arrival in lysosomes, the detection of V/L/L molecules at the 
cell surface of cells not treated with leupeptin would strongly 
suggest that newly synthesized V/L/L molecules can pass 
through the plasma membrane before lysosomal delivery. 
We determined the relative number of V/L/L molecules in 
the plasma membrane of cells expressing V/L/L with or 
without leupeptin treatment by measuring the binding of 
t25I-VSV-G-mAb to non-permeabilized as well as permeabi- 
lized cells (Table II). 0.7 % of the total VSV-G-mAb binding 
sites were found at the cell surface in leupeptin treated ceils 
while  3.3 %  of the  total VSV-G-mAb  binding  sites  were 
found at the cell surface without leupeptin treatment. As 
would be expected, the total number of VSV-G-mAb binding 
sites increased substantially (sixfold in  16 h  of leupeptin 
treatment). The absolute number of V/L/L molecules at the 
cell surface, however, did not change dramatically (only 1.3- 
fold). Thus, the steady state level of V/L/L in the plasma 
membrane is relatively independent of the accumulation of 
V/L/L molecules in lysosomal membranes. 
A Wave of  Recently Synthesized V/L/L and LEPIO0 
Molecules Passes through the Cell Surf  ace  following a 
Synchronized t~lse of  Expression 
The transient expression of recently synthesized V/L/L or 
LEP100 molecules in the plasma membrane was visualized 
by immunofluorescence microscopy following synchronized 
expression with the recombinant vaccinia virus/T7 system. 
L cells pre-treated for 4 h with leupeptin were infected with 
recombinant vaccinia virus and 30 min later transfected with 
V/L/L-DNA or LEP100-DNA cloned just 3' to the T7 pro- 
moter in pBluescript.  In  these experiments the  T7  RNA 
polymerase-driven synthesis of V/L/L or LEP100 was al- 
lowed to proceed for a maximum of 4 h, terminated by addi- 
tion of CHX.  At 4  h  the  predominant intracellular  im- 
munofluorescence was in the ER (identified by the presence 
of a circum-nuclear ring) and intense perinuclear labeling 
taken to be Golgi apparatus (Fig. 7 A). Lysosomal labeling 
was not apparent.  Labeling of the plasma membrane was 
strong at this time, however (Fig. 7, B and D). Ceils still ex- 
pressed V/L/L at the surface 1 h after the addition of CHX 
(Fig. 7 E).  After 2 h in CHX almost no surface labeling 
could be detected (Fig. 7 F) and the characteristic lysosomal 
pattern of immunofluorescence was  seen (see Fig.  9  C). 
Comparable results were obtained for LEP100 expression. 
The expression of V/L/L at the cell surface was independent 
of the lysosomal accumulation of V/L/L. Without leupeptin 
treatment V/L/L was readily detected both on the cell sur- 
face and in the ER and Golgi regions, but it did not accumu- 
late in lysosomes and it disappeared completely within 2 h 
of CHX treatment. 
Cell Surface V/L/L Rapidly Cycles Between the 
Plasma Membrane and Endosomes and Is Transported 
more Slowly to Lysosomes 
In chicken fibroblasts a few percent of  LEP100 molecules are 
found in the plasma membrane, and these undergo continu- 
ous, rapid exchange with a larger population of molecules in 
early  endosomes  (Lippincott-Schwartz  and  Fambrough, 
1986, 1987). Cell-surface V/L/L molecules were also found 
to exchange rapidly with intracellular molecules (Fig. 8 A). 
When cell-surface V/L/L molecules  were  saturated with 
VSV-G-mAb  at 4~  and the cells subsequently warmed to 
37~  a new population of binding sites for VSV-G-mAb ap- 
peared at the surface with a half-time of  two to three minutes. 
In this experiment a small fraction of the newly appearing 
molecules should be attributable to newly synthesized mole- 
cules arriving from the Golgi apparatus. The kinetics of such 
a component should be linear (whereas recycling kinetics are 
exponential) and its magnitude might be •20%  of the mole- 
cules detected in the warm-up period, an effect too small to 
be seen clearly in experiments such as shown in Fig. 8 A. 
The  rate  of internalization of 12sI-VSV-G-mAb bound  to 
V/L/L molecules from the cell surface at 37~  was also very 
rapid (Fig. 8 B). 
In chicken embryo fibroblasts, LEP100 is internalized from 
the plasma membrane and transported to lysosomes. When 
cells were exposed to LEP100-mAb, the antibody was car- 
ried to lysosomes and accumulated there if cells were treated 
with leupeptin (Lippincott-Schwartz and Fambrough, 1987) 
(Fig. 9 C). The same sort of process occurred in cells ex- 
pressing the V/L/L chimera: grown in medium containing 
VSV-G-mAb  and  leupeptin,  the  cells  accumulated VSV- 
G-mAb and showed the punctate, lysosomal pattern of flu- 
orescence  when  subsequently permeabilized  and  labeled 
with fluorescem anti-mouse-IgG second antibody (Fig. 9, A 
and B). 
Cell Surface Appearance of  Newly Synthesized V/L/L 
Is Not an Artifact of Overexpression 
In the recombinant vaccinia expression system there is mas- 
sive synthesis of V/L/L (making it easy to demonstrate the 
cell surface appearance of newly synthesized V/L/L by ira- 
The Journal of Cell Biology, Volume 118,  1992  1034 Figure 7. A wave of WL/L passes through the plasma membrane following synchronized expression using the vaccinia virus/T7  system. 
30 min after Ltk- cells were infected with vaccinia virus/T7,  DNA encoding V/L/L was introduced as a DNA/lipofectin complex.  This 
complex was prepared as a stock solution and an equal volume added to each coverslip. 4 h later the medium was replaced with medium 
containing 75 #g/ml cycloheximide. After additional incubation, cells were fixed and labeled with VSV-G-mAb and then FITC-conjugated 
goat anti-mouse antibody. Immunofluorescence micrographs of representative cells are shown at each time point following cyclobeximide 
addition.  For total cell staining,  20 #M leupeptin was added to dishes to be transfected with V/L/L four hours prior to vaccinia virus 
infection: this concentration of leupeptin was maintained throughout the experiment.  (A) Total cell labeling with 0 h CHX treatment. (B) 
The same cell as in A with the plane of focus adjusted to show cell surface labeling. (C) Total cell labeling following 2 h CHX treatment. 
(D) Cell surface labeling (without saponin) at 0 h CHX treatment.  (E) Cell surface labeling at 1 h CHX treatment. (F) Cell surface labeling 
at 2 h CHX treatment.  Bar,  10 mm. 
munofluorescence  microscopy) (Fig.  7).  It is  conceivable 
that this level of expression might swamp an intracellular 
sorting mechanism and lead to misdirection of V/L/L mole- 
cules to the cell surface. However, with the exception of ex- 
periments documented in Fig. 7, the experiments describing 
the behavior of V/L/L molecules were conducted with stable 
L  cell lines expressing V/L/L in response to induction by 
butyrate. To assess the effect of expression level on appear- 
ance of V/L/L at the cell surface in these cells, we conducted 
a  series of experiments at different levels of expression.  In 
these experiments we measured the average number of V/L/L 
molecules per cell (Table III). Expression levels appeared to 
be less than or comparable to the expected endogenous level 
of expression of LEP100 type molecules (see Discussion). 
Then  we  performed  experiments  to  assess  the  relative 
number of V/L/L molecules coming  to the  plasma mem- 
brane en route to lysosomes at lower and higher levels of ex- 
pression in these same cultures.  The population of V/L/L 
molecules in these cultures consists almost entirely of mole- 
cules in the biosynthesis and targeting pathway. If cultures 
could be exposed to an infinite concentration of ~25I-VSV-G- 
mAb, every molecule of V/L/L coming to the plasma mem- 
brane would become labeled. If  lysosomal degradation could 
be inhibited  quantitatively and instantly by leupeptin,  this 
antibody would accumulate in lysosomes in amounts identi- 
cal  to  the  number  of V/L/L  molecules  that  had  passed 
through the plasma membrane compartment. If this experi- 
ment were done by adding leupeptin, cycloheximide, and the 
~25I-VSV-G-mAb to the culture medium simultaneously, by 
2 h the V/L/L-mediated uptake of antibody would cease. If 
all the V/L/L passed through the plasma membrane com- 
partment,  an  amount  of  antibody  equal  to  the  starting 
amount of V/L/L would have accumulated in the lysosomes. 
In  practice,  the  inhibition  of  lysosomal  degradation  by 
leupeptin develops slowly (Fig.  4)  even at high concentra- 
tions of leupeptin,  and the binding of antibody to antigen 
proceeds with a half-time of a few minutes at practical anti- 
body concentrations. Nevertheless, this experimental design 
can be employed to assess the relative amount of V/L/L pass- 
ing through the cell surface en route to lysosomes at the vari- 
ous expression levels.  The results of such experiments are 
tabulated in Table IV and the experimental details are de- 
scribed in the legend.  The V/L/L-dependent uptake of ~5I- 
VSV-G-mAb did plateau by 100 min, as expected (data not 
shown),  and at 2  h  the cells contained  an amount of ~I- 
VSV-G-mAb equal to the amount of V/L/L present in paral- 
lel cultures treated for 2 h with leupeptin and cycloheximide. 
These results  were independent  of the  level of V/L/L ex- 
pression. 
Discussion 
The Cytoplasmic Domain of  LEPIO0 Is Necessary and 
SuJ~cient for Lysosomal Targeting 
This  study  began  as  an  exploration  of  the  location  of 
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Figure  8.  Cycling of V/L/L 
at  the  plasma  membrane. 
(A) Cell-surface  VSV-G-mAb 
binding  sites were blocked by 
incubating cell lines of  V/L/L- 
expressing cells with excess an- 
tibody (50 #g/ml) at 4~  Fol- 
lowing warm-up at 37~  cells 
were  fixed  at  the  indicated 
times  and  125I-VSV-G-mAb 
binding  sites  measured.  (B) 
~:5I-VSV-G-mAb was  bound 
for 6 h at 4~  to the surface of 
living L cells expressing V/L/L 
or VSV-G grown in 35-mm- 
diam tissue culture dishes. Af- 
ter warming  to 37~  for the 
times specified,  surface-asso- 
ciated antibody was eluted by 
treating  for  5  min  with  ice- 
cold 0.1 M acetic acid, 1.5 M 
NaC1. t25I-VSV-G-mAb  eluted 
by this low pH, high-salt treat- 
ment is plotted as a percentage 
of  radiation  eluted  without 
37~  warm up.  For both ex- 
periments, each data point rep- 
resents  the  average  measure- 
ment for a  set of five dishes 
of cells. 
lysosomal  targeting  information  in  the  LEP100 molecule. 
The parent molecules (LEP100 and VSV-G) and all six possi- 
ble  topologically  equivalent  chimeras  involving  their  ec- 
todomain, transmembrane domain, and cytoplasmic domain 
(L/L/V, L/V/V, V/L/V, V/L/L, and L/V/L, and V/V/L) were 
expressed in mouse L-cells. All chimeras containing the cy- 
toplasmic  domain  of LEP100  accumulated  in  lysosomes; 
those that did not,  accumulated in the plasma membrane. 
These results confirm and extend similar work by Williams 
and Fukuda (1990) that explored the targeting information in 
the cytoplasmic domain of hLAMP-1, which has a cytoplas- 
mic domain identical to that of LEP100. In their work, muta- 
tions of the  single Tyr in this  domain to Ala,  Ser,  or Thr 
resulted in accumulation of the mutant hLAMP-1 molecules 
in the plasma membrane.  The normal cytoplasmic domain 
was shown to be sufficient for lysosomal targeting of a chi- 
Figure  9.  Antibody uptake by cells 
expressing  V/L/L and LEP100.  Sta- 
bly  transfected  L  cell  lines  were 
plated  onto  glass  coverslips.  After 
30 h  of butyrate induction,  20 #M 
leupeptin,  and 5 #g/ml VSV-G-mAb 
(V/L/L expressing cells) or LEP100- 
mAb (LEP100 expressing cells) were 
added to the butyrate-containing me- 
dium.  Incubations  were  continued 
for an additional  12  h.  Ceils  were 
then washed  extensively  with PBS, 
fixed, and incubated with FI'IC-con- 
jugated goat anti-mouse antibody in the presence of saponin.  (A) Immunofluorescence micrograph of a single cell expressing  V/L/L. (B) 
Phase contrast photomicrograph of the same cell,  showing surrounding cells not expressing  V/L/L. (C) Immunofluorescence micrograph 
of a cell  expressing  LEP100.  Bar,  10 #m. 
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Mouse Cell Lines 
Butyrate  Cells (X  10  6)  V/L/L molecules  V/L/L molecules 
treatment  per dish  per culture  per cell 
(h) 
0  3.8  1.1  ￿  lO  s  29 
22  3.7  7.6  x  lO  s  210 
24  3.8  1.9  x  109  520 
25  3.2  1.8  )<  109  550 
48  3.2  7.1  X  109  2,210 
50  3.5*  1.6  X  101~  4,570 
Confluent cultures of mouse cells stably transfected with DNA encoding V/L/L 
were induced in 10 mM butyrate  containing medium for the specified times. 
Cell  numbers  were calculated  from direct  counts  on phase  micrographs  of 
representative areas of the cultures at the time of analysis and varied between 
3.2  and 3.8  ￿  106 per dish. 
Numbers of V/L/L molecules were determined as the numbers of specific ~2~I- 
VSV-G-mAb binding sites in saponin permeabilized cells,  using t2~I-VSV-G- 
mAb of known specific activity  (see Materials and Methods). 
* Indicates experiment  in which cell numbers  in the confluent cultures  were 
not counted but only estimated as the average of the values found in the other 
experiments. 
meric protein that consisted of a secretory protein, human 
gonadotropin a-chain, linked to the transmembrane domain 
of  VSV-G, and the cytoplasmic domain of  hLAMP-1. Whether 
the lumenal or transmembrane domains of hLAMP-1 might 
also contain lysosomal targeting information was not ex- 
plored. 
The Lumenal Domain and Transmembrane Domain 
of  LEPIO0 Are Neither Necessary Nor Sufficient for 
Lysosomal Targeting of Chimeras, and the 
Lumenal Domain of  LEPIO0 Expressed Alone Is a 
Secretory Protein 
Chimeras between LEP100 and VSV-G that lacked the cyto- 
Table IV. Effect of  Expression Level on V/L/L-mediated 
1251-VSV-G-mAb Uptake 
V/L/L per cell  VSV-G-mAb uptake 
Butyrate  V/L/L molecules  after 2 h  per cell after 2 h 
treatment  expressed per cell  in CHX +  leupeptin  in CHX +  leupeptin 
(h) 
22  210  ND  60 
24  520  110  300 
25  550  180  180 
48  2,210  510  420 
50  4,570  1,920  1,960 
Confluent cultures of mouse cells stably transfected with DNA encoding V/L/L 
were induced in 10 mM butyrate containing medium for the specified times. 
Numbers of V/L/L molecules per cell (colunm 2) are taken from Table III. Sets 
of cultures from the same batches were exposed to leupeptin (80 or 100 #g/ml) 
and CHX for 2 h, fix, permeabilized,  and specific ~2~I-VSV-G-mAb  binding 
sites determined.  In parallel,  other cultures were maintained in medium with 
leupeptin and CHX for 2 h at 37"C in the presence  of 1 #g/ml mI-VSV-G- 
mAb with (three or five dishes) or without (two or three dishes) a 50-fold ex- 
cess unlabeled antibody. After the 2-h incubations, cultures wre washed at 4"C 
and radioactivity measured in a gamma counter.  Number in the third colunm 
were calculated by multiplying the number of V/L/L molecules per cell (sec- 
ond column)  by the  ratio  of specific  ~251-VSV-G-mAb binding  to CHX  + 
leupeptin treated cells vs. binding to untreated cells. To obtain the numbers in 
the fourth column,  specific uptake was calculated by subtracting uptake in the 
presence  of 50-fold  unlabeled antibody  from total  ~251-mAb uptake.  Specific 
uptake was converted to molecules of antibody taken up per cell by using the 
known specific activity of the antibody (Materials and Methods) and the num- 
ber of cells per culture dish (Table IN). 
plasmic domain of LEP100 were not targeted to lysosomes 
even if they contained the lumenal domain or the transmem- 
brane domain of LEP100 or both. Since it was conceivable 
that a strong plasma membrane targeting signal in the cyto- 
plasmic domains of chimeras and mutants might override a 
lysosomal targeting signal in the lumenal domain of  LEP100, 
a truncated form lacking the transmembrane and cytoplas- 
mic domains of LEP100  was  expressed.  It was  secreted 
efficiently  by the cells and only unprocessed precursor could 
be detected in cell lysates. The prevailing idea has been that 
lysosomal membrane proteins are sorted for targeting to the 
lysosomes at the trans-Golgi network (TGN)  (see Green et 
al.,  1987; Kornfeld  and  Mellman,  1989;  Williams  and 
Fukuda,  1990;  Hunziker et al.,  1991). Soluble lysosomal 
proteins are sorted at this site and sent to lysosomes by a pro- 
cess mediated in part by M6P receptors (reviewed in Korn- 
feld and  Mellman,  1989).  If this  were  the  case  for the 
lysosomal membrane proteins, any bias towards lysosomal 
sorting should have sent some of the truncated LEP100 to 
lysosomes. 
The Lumenal Domain of  LEPIO0 Stabilizes 
LEPIO0 in the Lysosome but Fails to Protect the 
Lumenal Domain of  Nearby V/L/L Molecules 
To observe the lysosomal delivery of chimeric proteins lack- 
ing the lumenal domain of LEP100 it was necessary to block 
lysosomal proteases  with leupeptin.  Even  with leupeptin 
treatment,  the  VSV-G domain was  clipped  rapidly upon 
delivery of the chimeras to lysosomes. Immunofluorescence 
microscopy showed clearly that newly synthesized mole- 
cules are delivered to most or all of the lysosomes in the cell 
and therefore newly arriving molecules must exist in a sur- 
round  of  endogenous  lysosomal membrane  glycoprotein 
molecules. The half-life in lysosomes of chimeras containing 
the VSV-G domain is no more than a few minutes, whereas 
that of LEP100 is about two days (Lippincott-Schwartz and 
Fambrough,  1986, 1987). 
Most or All Chimeric Molecules Directed to the 
Lysosome by the LEPIO0 Cytoplasmic Domain Are 
First Incorporated into the Plasma Membrane 
The V/L/L chimera was most useful in determining the path- 
way taken by newly synthesized molecules to the lysosome 
because the VSV-G ectodomain was rapidly degraded upon 
delivery  to  lysosomes.  Pulse/chase  experiments  (Fig.  6) 
showed that many of the V/L/L molecules in expressing cells 
had not been processed by Golgi enzymes and that Golgi- 
processed molecules were degraded within minutes. Rapid 
loss of the population of V/L/L molecules when protein syn- 
thesis was inhibited is consistent with this interpretation of 
the  pulse/chase  experiments.  Leupeptin  treatment of the 
cells stabilized the V/L/L molecules, allowing them to ac- 
cumulate in lysosomes (Figs.  2 and 4).  The movement of 
newly synthesized V/V/L and V/L/L through the plasma 
membrane  was  shown  most  graphically  in  the  pulse- 
expression experiments (Fig. 7).  Although the time resolu- 
tion was limited in those experiments, the detection of  V/L/L 
molecules in the plasma membrane for up to 1 h after CHX 
treatment, but not after 2 h, is consistent with the kinetics 
of  V/L/L transport through the biosynthetic pathway (includ- 
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experiments. 
The rapid degradation of the VSV-G ectodomain in lyso- 
somes predicts that compartments  upstream from the lyso- 
some should contain newly synthesized V/L/L molecules 
regardless of leupeptin treatment whereas the lysosome and 
compartments downstream from the lysosome should con- 
tain V/L/L molecules  only following leupeptin  treatment. 
Therefore, the relative insensitivity of  the number of  cell sur- 
face V/L/L molecules to leupeptin treatment is strong evi- 
dence that the plasma membrane is upstream from the lyso- 
some  (Table II).  The  slightly  greater  number  of V/L/L 
molecules found in the plasma membrane following 16 h of 
leupeptin treatment may reflect the presence of older mole- 
cules at the cell surface which, due to leupeptin treatment, 
have accumulated in lysosomes and have cycled out of lyso- 
somes  back  to  the  plasma  membrane,  as  described  for 
LEP100 molecules in chick fibroblasts (Lippincott-Schwartz 
and Fambrough,  1986, 1987). 
In cells expressing V/L/L, the steady-state expression of 
V/L/L in the plasma membrane was ".,4% of  the V/L/L  mol- 
ecules. Since about half of the V/L/L molecules were in the 
high-mannose state characteristic of location in the ER (Fig. 
6 A) and another fraction of V/L/L molecules must be in the 
Golgi apparatus, the post-Golgi compartments are expected 
to contain roughly 25 % of the V/L/L molecules. The 4 % of 
molecules  in the plasma membrane  are in rapid  exchange 
with an endosomal pool of V/L/L molecules, and the size of 
this pool can be estimated from the curves in Fig. 8 (for dis- 
cussion see Lippincott-Schwartz and Fambrough,  1987) to 
be about four to five times the size of the plasma membrane 
population, or around 20% of total V/L/L molecules. Thus 
the size of the combined populations  of V/L/L molecules 
rapidly exchanging between the plasma membrane and endo- 
somes is about the size of the entire post-Golgi population. 
While this study does not completely rule out the possibility 
that some molecules traveled more directly from the TGN to 
lysosomes, direct transport of a significant fraction of mole- 
cules is unlikely. 
In our experiments the levels of V/L/L in the biosynthesis/ 
targeting pathway ranged up to "o4,500 molecules per cell 
(Table III). While we do not have exact data for the quantity 
of the endogenous homolog of LEP100 (m-lamp-I) in these 
cells, this value must be similar to that reported  for chick 
fibroblasts  (Lippincott-Schwartz  and  Fambrough,  1986): 
nearly 400,000 molecules per cell. These endogenous mole- 
cules have a metabolic half-life of about 40 h, and therefore 
to sustain an endogenous level of even 200,000 molecules 
per cell,  a biosynthetic  rate of about 5,000 molecules per 
hour would be required.  Moreover, there are probably sev- 
eral different lysosomal membrane proteins that employ the 
same sorting machinery, and therefore the sorting machinery 
normally  processes  roughly  10,000 molecules/h.  Thus,  it 
seems unlikely that the exogenously expressed V/L/L dis- 
turbs the sorting/targeting behavior of the cells, even if ex- 
pression levels varied considerably  from cell to cell in the 
population.  This is supported by the data in Table IV that 
show no effect of expression levels on V/L/L-mediated  anti- 
body uptake. The antibody uptake data do not in themselves 
distinguish  between  appearance  of antigen  at the plasma 
membrane or the flow of medium through the endocytic path- 
way by fluid phase uptake and then exocytosis (Besterman 
et al., 1981; Adams et al., 1982; Swanson et al., 1985; Swan- 
son,  1989; Bomsel et al., 1989) with retention in the endo- 
somes being antigen dependent. However, the experiments 
that directly demonstrate cycling (Fig. 8) suggest that large 
volume fluid flow through the endocytic pathway need not be 
invoked to account for antibody uptake. In either mechanism 
newly synthesized LEP100-type  molecules must be in the 
plasma membrane/early endosome compartment to mediate 
the saturable uptake of antibody. 
Recently Harter and Mellman (1992) demonstrated that 
high  levels of over-expression  of lgpl20  (a  homolog  of 
LEP100) in CHO cells resulted in higher steady state levels 
on the plasma membrane.  Hatter and Mellman (1992) also 
reported immunofluorescence evidence for enhanced surface 
expression of  another endogenous lysosomal membrane pro- 
tein in the over-expressing cells and interpreted this as mis- 
sorting  resulting  from competition  with  exogenously ex- 
pressed lgp120 for sorting receptors  in the TGN. In these 
experiments the expression levels were up to 15 times the en- 
dogenous; at these levels sorting might be significantly per- 
turbed. Harter and Mellman (1992) also reported that in non- 
transfected pulse-labeled NRK cells 3~S-labeled lgp120 was 
detected at the plasma membrane (1.8 % of total) by biotiny- 
lation of cells at 0~  a level not greatly different from the 
4% V/L/L found at the surface of fixed cells in our experi- 
ments. The small size of this fraction is not directly an indi- 
cator of the significance of the cell surface in the transport 
pathway to lysosomes. This size depends upon the balance 
between distribution  in surface and early endosome com- 
partments as well as the rate of exit from early endosomes 
in the pathway to lysosomes. 
Most of the results reported here involve the behavior of 
V/L/L molecules. We have made the assumption that the ec- 
todomain of  VSV-G protein is behaving passively in the sort- 
ing/targeting behavior of  the chimera. We cannot rule out the 
possibility  that this domain somehow masks the targeting 
signal for direct delivery of LEPI00 from the TGN to lyso- 
somes. Clearly it does not prevent efficient delivery to lyso- 
somes via the cell surface. 
The Major Pathway  of Targeting LEPIO0 to the 
Lysosomes Includes the Plasma Membrane 
Our data fit a model in which newly synthesized LEP100 is 
transported to the cell surface early endosome compartment, 
is shuttled rapidly between the plasma membrane and endo- 
somes by endocytosis and exocytosis, and is then delivered 
to lysosomes. Because of this rapid  shuttling, it would be 
very difficult to distinguish direct transport of newly synthe- 
sized LEP100 molecules  from the Golgi  apparatus  to the 
plasma membrane  from indirect transport via early endo- 
somes. Our data are not consistent with the TGN being the 
site of sorting of LEP100-type lysosomal membrane glyco- 
proteins for delivery to late endosomes or lysosomes. 
If the plasma membrane is in the pathway for lysosomal 
targeting of  a lysosomal membrane protein, then that protein 
must have a structure  suitable for efficient endocytosis.  A 
number of integral membrane proteins undergo endocytosis 
as a normal part of their function (Ktistakis et al.,  1990). 
This process generally depends upon the structure of their 
cytoplasmic  domain,  e.g.,  the  LDL receptor  (Lerman et 
al.,  1985; Davis et al.,  1987), the EGF receptor  (Prywes 
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al.,  1986), the transferrin receptor (Rothenberg et al.,  1987), 
and the Fc receptor  (Miettinen  et al.,  1989).  At least one 
tyrosine occurs in the cytoplasmic domain of each of these 
receptors, and, where it has been examined, changing a criti- 
cal tyrosine either eliminates or greatly reduces endocytosis 
(e.g.,  Davis  et al.,  1987;  Lobel  et al.,  1989;  Jing et al., 
1990). This is also true for the transmembrane form of LAP 
(Peters et al.,  1990).  Mutations of the tyrosine in the cyto- 
plasmic domain of hLAMP-1  and lgpl20  result in proteins 
that  accumulate  in  the  plasma  membrane  (Williams  and 
Fukuda,  1990;  Hunziker et al.,  1991).  In light of our data 
showing the passage of newly synthesized LEP100, V/V/L, 
and V/L/L through the plasma membrane and the secretion 
of the truncated  LEP100,  it appears  that accumulation of 
these mutants in the plasma membrane results from a defect 
in endocytosis and not from missorting in the TGN. 
Although the cytoplasmic domains of the lysosomai mem- 
brane  proteins  share  features of a  tyrosine-contalning  en- 
docytosis  motif with  the plasma membrane receptors  dis- 
cussed  above  (Ktistakis  et  al.,  1990),  plasma  membrane 
receptors generally avoid delivery to the lysosome.  It is an 
interesting possibility that there may be a graded set of inter- 
nalization signals:  from those involved mainly in endocyto- 
sis to those involved in endocytosis and efficient lysosomal 
delivery. In fact, the properties of these signals may regulate 
not only subcellular distribution of membrane proteins but 
also their lifetimes, by determining the probability that they 
will be transported from endosome to lysosome. 
Recent  experiments  in  MDCK  cells  indicate  that most 
molecules of LAMP-2 (at least 70%) are targeting basolater- 
ally before lysosomal delivery (Nabi et al.,  1991). LAMP-2 
(Fukuda et al., 1988; Cha et al., 1990; Granger et al.,  1990) 
is a type of lysosomal membrane glycoprotein closely related 
to the LEP100/LAMP-1  type. Human LAP, a lysosomal en- 
zyme synthesized as a transmembrane protein, has also been 
shown to travel to the plasma membrane before endocytosis, 
delivery to lysosomes, and cleavage to the soluble form (Wa- 
heed et al., 1988; Braun et al., 1989). Our studies of LEP100 
together with the data on the other lysosomal glycoproteins, 
LAMP-2  and LAP,  suggest that the delivery of transmem- 
brane proteins to the lysosome via the cell surface is a major 
pathway in animal cells. 
The  question  of  a  branched  pathway  (as  proposed  by 
Harter and Mellman, 1992) or quantitative delivery of newly 
synthesized lamp-type molecules to the cell surface/early en- 
dosome cycle, as argued here, cannot easily be resolved with 
present technologies. Since it is virtually impossible to prove 
a negative, the existence of a minor direct pathway from TGN 
to lysosomes cannot be disproved. The apparent quantitative 
differences between cell types might reflect different balances 
of direct and indirect pathways or simply different kinetics 
of individual transport steps in the cell surface route to lyso- 
somes. The biosynthetic rate of the LEP100-type lysosomal 
membrane proteins is very modest, for they have long life- 
times in the cells. It would not require very robust expression 
of sorting machinery to deliver newly synthesized molecules 
efficiently  from the TGN to lysosomes if that were the in- 
tended biological route. There must be an important biologi- 
cal reason for sending LEP100 to the surface before retrieval 
and targeting to lysosomes.  One exciting possibility is that 
this targeting route plays a normal role in cell-cell  or cell- 
matrix interactions. 
We wish to  thank  Jack  Rose for  VSV-G cDNA, Doug Lyles for  the  hybrid- 
oma secreting  VSV-G-mAb,  Tom August for mLAMP-I-mAb,  Carolyn 
Machamcr for  help  with  the  vaccinia  virus/T7  expression  system, Delores 
Somerville  for  technical  assistance,  and Robert Nabi, Joel  Swanson, Paul 
Kessler,  Mark Emerick, and Christine  Hatem for  their  suggestions  during 
the writing of the manuscript. 
This work  was  supported by National Institutes  of Health grant 
NS-2324  I. 
Received for publication 31  January  1992 and in revised form  17 June 
1992. 
References 
Adams, C. J., K. M. Maurey, and B. Storrie.  1982.  Exocytosis of pinocytic 
contents by chinese hamster ovary cells. J.  Cell Biol. 93:632-637. 
Anderson, M. J., and D. M. Fambrough. 1983.  Aggregates of acetylcholine 
receptors are associated with plaques of a basal lamina heparan sulfate pro- 
teoglycan on the surface of skeletal  muscle fibers. J.  Cell Biol. 97:1396- 
1411. 
Barriocanal, J. G., J. S. Bonifacino, L. Yuan, and I. V. Sandoval. 1986. Bin- 
synthesis, glycosylation, movement  through  the Golgi system, and transport 
to lysosomes by an N-linked carbohydrate-independent mechanism  of three 
lysosomal integral membrane proteins. J. Biol. Chem. 261:16744-16763. 
Besterman, J. M., J. A. Airhart, R. C. Woodworth, and R. B. Low. 1981. Exo- 
cytosis of pinocytosed fluid in cultured cells: kinetic evidence for rapid turn- 
over and compartmentatinn. J.  Cell Biol. 91:716-727. 
Bomsel, M., K. Prydz, R. G. Parton, J. Gruenberg, and K. Simons. 1989. En- 
docytosis in filter-grown Madin-Darby canine kidney cells. J.  Cell Biol. 
109:3243-3258. 
Braun, M., A. Waheed, and K. yon Figura. 1989. Lysosomal acid phosphatase 
is transported to lysosomes  via the cell surface. EMBO (Eur. Mol. Biol. Or- 
gan.) J.  8:3497-3506. 
Brewer, C. B., and M. G. Roth. 1991. A single amino acid change in the cyto- 
plasmic domain alters the polarized  delivery of influenza virus hemaggluti- 
Pin. J.  CelI Biol. 114:413-421. 
Brown,  W.  J.,  J.  Goodhouse,  and  M.  G.  Farquhar.  1986.  Mannose-6- 
phosphate receptors for lysosomal  enzymes cycle between the Golgi complex 
and endosomes. J.  Cell Biol. 103:1235-1247. 
Cha, Y., S. M. Holland, and J. T. August. 1990. The eDNA sequence  of mouse 
LAMP-2. J.  Biol. Chem. 265:5008-5013. 
Cben, J. W., T. L. Murphy, M. C. Willingham, I. Pastan, and J. T. August. 
1985. Identification  of two lysosomal membrane glycoproteins. J.  CellBiol. 
101:85-95. 
Chert, J. W., Y. Cha, K. U. Yuksel, R. W. Gracy, and J. T. August. 1988. 
Isolation  and sequencing of a eDNA clone encoding lysosomal membrane 
glycoprotein mouse LAMP-I. J.  Biol. Chem. 263:8754-8758. 
Davis, C. D., I. R. van Driel, D. W. Russell, M. S. Brown, andJ. L. Goldstein. 
1987. The low density lipoprotein receptor: identification  of amino acids in 
cytoplasmic  domain  required  for  rapid  endocytosis.  J.  Biol.  Chem. 
262:4075-4082. 
D'Sonza, M. P., and J. T. August. 1986. A kinetic analysis of biosynthesis and 
localization  of a lysosome-associated membrane glycoprotein. Arch.  Bio- 
chem. Biophys.  249:522-532. 
Duncan, J. R., and S. Korufeld. 1988. Intracellular movement of two mannose 
6-pbosphate  receptors:  return  to  the  Golgi  apparatus.  J.  Cell Biol. 
106:617-628. 
Fambrough, D. M., and E. K. Bayne. 1983.  Multiple forms of (Na  § +  K+)  - 
ATPase in the chicken. J.  Biol. Chem. 258:3926-3935. 
Fambrough, D. M., K. Takeyasu, J. Lippincott-Schwartz, and N. Siegel.  1988. 
Structure ofLEP100, a glycoprotein that shuttles between lysosomes and the 
plasma membrane, deduced from the nucleotide sequence of the encoding 
eDNA. J.  Cell BioL 106:61-67. 
Fuerst, T. R.,  E.  G. Niles, F. W. Studier, and B. Moss.  1986.  Eukaryotic 
transient-expression  system  based on recombinant vaccinia virus that synthe- 
sizes bacteriophage  T7  RNA  polymerase. Proc.  Natl. Acad. Sci. USA 
83:8122-8126. 
Fukuda, M., J.  Viitala, J.  Matteson, and S. R.  Carlsson. 1988.  Cloning of 
cDNAs encoding human lysosomal membrane glycoproteins, h-lamp-1 and 
h-lamp-2. J.  Biol. Chem. 263:18920-18928. 
Goda, Y.,  and S.  R.  Pfeffer.  1988.  Selective  recycling of the mannose 6- 
phosphate/IGF-II  receptor  to  the  trans  Golgi  network  in  vitro.  Cell. 
55:309-320. 
Gorman, C. M., B. H. Howard, and R. Reeves. 1983.  Expression of recom- 
binant plasmids in mammalian  cells is enhanced by sodium butyrate. Nucleic 
Acids Res. 11:7631-7648. 
Granger, B. L., S. A. Green, C. A. Gabel, C. L. Howe, I. Mellman, and A. 
Helenius. 1990. Characterization and cloning of lgp110, a lysosomal mem- 
brane glycoprotein from mouse and rat cells. J.  Biol. Chem. 265:12036- 
12043. 
Green, S. A., K.-P. Zimmer, G. Griffiths,  and I. MeUman.  1987. Kinetics of 
intracellular transport and sorting of lysosomal membrane and plasma mem- 
brane proteins. J.  Cell Biol. 105:1227-1240. 
Mathews et al. Lysosomal  Targeting of LEPIO0  1039 Griffiths, G., and K. Simons. 1986. The trans Golgi network: sorting at the exit 
site of the Golgi complex. Science  (wash.  DC),  243:438--443. 
Griffiths,  G., B. Hoflack,  K. Simons, I. Mellman, and S. Kornfeld. 1988. The 
mannose 6-phosphate receptor  and  the  biogenesis of lysosomes.  Cell. 
52:329-341. 
Halter, C., and I. Mellman. 1992. Transport of the lysosomal membrane  glyco- 
protein lgpl20 (lgp-A) to lysosomes does not require appearance on the 
plasma membrane. J.  Cell Biol.  117:311-325. 
Howe, C. L., B. L. Granger, M. Hull, S. A. Green, C. A. Gabel, A. Helenius, 
and I.  Mellman.  1988.  Derived protein  sequence, oligosaccharides, and 
membrane insertion  of  the  120-kDa  lysosomal membrane glycoprotein 
(lgpl20): identification of a highly conserved family of lysosomal membrane 
glycoproteins. Proc. Natl.  Acad. Sci. USA 85:7577-7581. 
Hunziker, W., C. Harter, K. Matter, and I. Mellman. 1991. Basolateral  sorting 
in MDCK cells requires a distinct cytoplasmic domain determinant. Cell. 
66:907-920. 
Jing, S., T. Spencer, K. Miller, C. Hopkins, and I. S. Trowbridge. 1990. Role 
of the human transferrin receptor cytoplasmic domain in endocytosis: local- 
ization  of  a  specific  signal  sequence  for  internalization.  J.  Cell Biol. 
110:283-294. 
Kit, S., D. R. Dubbs, L. J. Piekarski, and T. C. Hsu. 1963. Deletion of thymi- 
dine kinase activity from L ceils resistant to bromodeoxyuridine. Exp. Cell 
Res.  31:297-312. 
Kornfeld, S., and I. Mellman. 1989. The biogenesis of lysosomes. Ann. Rev. 
Cell Biol. 5:483-525. 
Ktistakis, N. T., D. N. Thomas, and M. G. Roth. 1990. Characteristics of the 
tyrosine recognition signal for internalization of transmembrane  surface gly- 
coproteins. J.  Cell Biol.  111:1393-1407. 
Kunkel, T. A., J. D. Roberts, and R. A. Zakour. 1987. Rapid and efficient site- 
specific  mutagenesis without  phenotypic  selection.  Methods  Enzymol. 
154:367-382. 
LeFrancois, L., and D. S. Lyles.  1982.  The interaction of antibody with the 
major surface glycoprotein of vesicular stomatitis virus: analysis of neu- 
tralizing epitopes with monoclonal antibodies.  Virology.  121:157-167. 
Lehrman, M. A., J.  L. Goldstein, M. S. Brown, D. W. Russell, and W. J. 
Schneider.  1985. Internalization-defective  LDL receptors produced by genes 
with nonsense and frameshift mutations that truncate the cytoplasmic do- 
main. Cell. 41:735-743. 
Lemansky, P., A. Hasilik, K. von Figura, S. Helmy, J. Fishman, R. E. Fine, 
N. L. Kedersh, and L. H. Rome. 1987.  Lysosomal enzyme precursors in 
coated vesicles derived from the exocytic and endocytic pathways. J.  Cell 
Biol.  104:1743-1748. 
Lippincott-Schwartz,  J., and D. M. Fambrough. 1986. Lysosomal membrane 
dynamics: structure and interorganellar movement of a  major lysosomal 
membrane glycoprotein. J.  Cell Biol.  102:1593-1602. 
Lippincott-Schwartz,  J., and D. M. Fambrough. 1987. Cycling of the integral 
membrane glyeoprotein,  LEP100,  between plasma membrane and  lyso- 
somes: kinetic  and morphological analysis. Cell. 49:669-677. 
Littlefield, J. W. 1964. Selection of hybrids from matings of fibroblasts in vitro 
and their presumed recombinants. Science  (wash.  DC).  145:709-710. 
Lobel, P., K. Fujimoto, R. D. Ye, G. Griffiths,  and S. Kornfeld. 1989. Muta- 
tions in the cytoplasmic domain of the 275 kd mannose 6-phosphate receptor 
differentially  alter  lysosomal enzyme sorting and endocytosis.  Cell. 57: 
787-796. 
Mane, S. M., L. Marzella, D. F. Bainton, V. K. Holt, Y. Cha, J. E. Hildreth, 
and  J.  T.  August.  1989.  Purification  and  characterization  of  human 
lysosomal membrane glycoproteins. Arch. Biochem. Biophy. 268:360-378. 
Marquardt, T., T. Braulke, A. Hasilik, and K. yon Figura. 1987.  Association 
of the precursor of cathepsin D with coated membranes: kinetics and carbo- 
hydrate processing. Eur. J.  Biochem. 168:37-42. 
McKnight, S. L.  1980. The nucleotide sequence and transcription map of the 
herpes simplex virus thymidine kinase gene. Nucleic Acids Res.  8:5949- 
5964. 
Miettinen, H. M., J. K. Rose, and I. Mellman. 1989. Fc receptor isoforms ex- 
hibit distinct abilities for coated pit localization as a result of cytoplasmic do- 
main heterogeneity. Cell. 58:317-327. 
Moss, B.  1991. Vaecinia virus: a tool for research and vaccine development. 
Science  (Wash. DC). 252:1662-1667. 
Mostov, K. E., A. de Brnyn Kops, and D. L. Deitcher. 1986. Deletion of the 
cytoplasmic domain of the polymeric immunoglobulin receptor prevents 
basolateral localization  and endocytosis. Cell. 47:359-364. 
Nabi, I. R., A. Le Bivic, D. Fambrough, and E. Rodrigucz-Boulan. 1991. An 
endogenous  MDCK lysosomal membrane glycoprotein is targeted basolater- 
ally before delivery to lysosomes. J.  Cell Biol. 115:1573-1584. 
Peters, C., M. Braun, B. Weber, M. Wendlan, B. Schmidt, R. Pohlmann, A. 
Waheed, and K. yon Figura. 1990. Targeting of a lysosomal membrane pro- 
tein:  a  tyrosine-containing endocytosis signal in the cytoplasmic tail  of 
lysosomal acid phosphatase is necessary and sufficient for targeting to lyso- 
somes. EMBO (Eur. Mol. Biol.  Organ.) J.  9:3497-3506. 
Prywes, R., E. Livneh, A. Ullrich, and J. Schlessinger. 1986. Mutations in the 
cytoplasmic domain of EGF receptor affect EGF binding and receptor inter- 
nalization.  EMBO (Eur. Mol. Biol. Organ.) J.  5:2179-2190. 
Rose, J. K., and A. Shafferman. 1981. Conditional expression of the vesicular 
stomatitis virus glycoprotein gene in Escherichia coli. Proc. Natl. Acad. Sci. 
USA 78:6670-6674. 
Rose, J. K., and J. E. Bergmarm. 1982. Expression from cloned cDNA of cell- 
surface secreted forms of the glycoprotein of vesicular stomatitis virus in eu- 
karyotic cells. Cell. 30:753-762. 
Rothenberger, S., B. J. Iacopetta,  and L. C. Kiihn. 1987.  Endocytosis of the 
transferrin receptor requires the cytoplasmic domain but not its phosphoryla- 
tion site. Cell. 49:423-431. 
Saiki,  R. K., D. H. Gelfand. S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, 
K. B. Mullis, and H. A. Erlich. 1988. Primer-directed enzymatic amplifica- 
tion of DNA with a thermostabile DNA polymerase. Science (Wash. DC). 
239:487-491. 
Salicinski, P. R. P., C. McLean, J. E. Sykes, V. V. Clement-Jones, and P. J. 
Lowry.  1981.  Iodination of proteins, glycoproteins, and peptides using a 
solid-phase oxidizing agent, 2,3,4,6-tetrachloro-3,6-diphenyl glycoluril (Io- 
dogen). Anal. Biochem.  117:136-146. 
Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain 
terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467. 
Small, J., and G. Scangos. 1984.  Expression of cotransferred genes in mouse 
L cells. Gene Anal. Tech. 1:13-17. 
Swanson. J. A. 1989. Phorbol esters stimulate  macropinocytosis  and solute flow 
through macrophages. J.  Cell Biol. 94:135-142. 
Swanson, J. A., B. D. Yirinec, and S. C. Silverstein. 1985. Phorbol esters and 
horseradish peroxidase stimulate  pinocytosis and redirect the flow of pinocy- 
tosed fluid in macrophages. J.  Cell Biol. 100:851-859. 
Takeyasu, K., M. M. Tamkun, N. R. Siegel, and D. M. Fambrough. 1987. 
Expression of hybrid (Na  + +  K+)-ATPase molecules after transfection of 
mouse LTK- cells with DNA encoding the B-subunit of an avian brain so- 
dium pump. J.  Cell Biol. 262:10733-10740. 
Viitalla,  J., S. R. Carlsson, P. D. Siebert,  and M. Fukuda. 1988.  Molecular 
cloning of cDNAs encoding lamp A, a human lysosomal membrane glyco- 
protein with apparent Mr "o120,000.  Proc. Natl. Acad. Sci. USA 85:3743- 
3747. 
von Figura, K., and A. Hasilik. 1986. Lysosomal enzymes and their receptors. 
Ann.  Rev. Biochem.  55:167-193. 
Wabeed, A., S. Gottschalk, A. Hille, C. Krentier, R. Pohlmann, T. Branlke, 
H.  Hauser, H.  Geuze, and K. yon Figura.  1988.  Human lysosomal acid 
phosphatase is transported as a transmembrane  protein to lysosomes  in trans- 
fected baby  hamster kidney  cells.  EMBO  (Eur. Mol. Biol. Organ.)  J. 
7:2351-2358. 
Williams, M. A., and M. Fukuda. 1990. Accumulation  of membrane  glycopro- 
teins in lysosomes requires a tyrosine residue at a particular position in the 
cytoplasmic tail.  J.  Cell Biol. 111:955-966. 
Zot, A. S., and D. M. Fambrough. 1990. Structure of a gene for a lysosomal 
membrane glycoprotein (LEP100).  J.  Biol. Chem. 265:20988-20995. 
The Journal of Cell Biology, Volume 118,  1992  1040 